Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff24/7 Wall Street • 02/16/26
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/16/26
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data showsReuters • 02/13/26
Hims & Hers Strengthens Integrated Personalized Digital Care PlatformZacks Investment Research • 02/12/26
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?Zacks Investment Research • 02/11/26
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk LawsuitThe Motley Fool • 02/09/26
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?The Motley Fool • 02/09/26
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug marketWSJ • 02/09/26
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New TurnInvestopedia • 02/09/26
Hims & Hers is scrapping its plan for a knockoff Wegovy weight-loss pill. Here's whyFast Company • 02/09/26